Skip to content
StockMarketAgent
Direct answer
Boston Scientific is a mature compounder in the medical device sector, benefiting from a diverse portfolio across cardiovascular, MedSurg, and rhythm management, generating strong operating cash flows and consistent margin expansion. Fair value range: low $55.9, high $85.0, with mid-point at $70.4.
Stock analysis

BSX BSX fair value $56–$85

BSX
By StockMarketAgent.AI team· supervised by
Przeanalizowano: 2026-05-12Następna aktualizacja: 2026-08-12Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
Cena
$54.10
▲ +16.29 (+30.11%)
Wartość godziwa
$70
$56–$85
Rekomendacja
Zdecydowanie kupuj
confidence 88/100
Potencjał wzrostu
+30.1%
upside to fair value
Margines Bezpieczeństwa
$59.83
MoS level · 15%
Kapitalizacja
$80.4B
P/E fwd 14.4
Awaryjny angielskiPL
Pokazujemy źródło angielskie podczas tłumaczenia
Ten raport nie został jeszcze przetłumaczony. Odśwież za kilka minut, gdy kolejka tłumaczeń go przetworzy.

§1 Podsumowanie wykonawcze

  • Strong Buy rating driven by 30% upside to $70.39 composite fair value midpoint.
  • Mature compounder profile translates high ROE into durable EPS growth with fading downside risk.
  • Q1 revenue growth of 11.6% outpaces major cardiovascular and MedSurg peers.
  • Valuation explicitly bridges benchmark optimism with structural terminal constraints via a moat-fade framework.
Fair value
$70
Margin of safety
+23.1%
Confidence
88/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$54.10Price
Low $55.91
Mid $70.39
High $85.05

Boston Scientific is a mature compounder in the medical device sector, benefiting from a diverse portfolio across cardiovascular, MedSurg, and rhythm management, generating strong operating cash flows and consistent margin expansion.

  • High switching costs in implantable
    High switching costs in implantable MedSurg devices.
  • Intangible assets via robust IP
    Intangible assets via robust IP in structural heart (WATCHMAN).
  • Cycle upside
    Demographic tailwinds and deferred elective procedure catch-up drive sustained, above-trend cardiovascular demand.

§2 Scenariusz negatywny

A severe macro shock testing hospital capital budgets exposes operating leverageLeverageThe proportion of debt in the company's capital structure. Commonly measured as Debt/EBITDA, Debt/Equity, or Net Debt/EBITDA. risks. With high fixed costs and a reinvestment rate of 82.6%, a top-line deceleration below 6% rapidly compresses the 20% operating marginOperating marginOperating income (EBIT) divided by revenue. Captures profitability after both direct costs and operating expenses but before interest, tax, and non-operating items., forcing fair valueFair valueOur composite estimate of intrinsic per-share value, blended across DCF, exit-multiple, and reverse-DCF methods. Reported as a low/mid/high range to capture model uncertainty. down toward the $55.91 bear floor.

Jak ta teza może się załamać

Multiple Compression to Peer Median

· Medium

Premium valuation collapses as the market forces reversion to peer median PEG ratios.

FV impact
Valuation plunges to $40.05 peg_adjusted_peer level.
Trigger
12-24 months

Reimbursement Rate Cuts

· Low

Medicare reimbursement cuts and hospital consolidation severely erode structural pricing power.

FV impact
Midpoint fair value drops to the $55.91 bear boundary.
Trigger
12-36 months

WATCHMAN Normalization Stall

· Medium

Accelerated market share gains in the structural heart segment fail, normalizing revenue growth abruptly.

FV impact
Pulls valuation below the $61.91 FCFF DCF baseline.
Trigger
6-18 months
Sygnały wczesnego ostrzegania do monitorowania
WskaźnikBieżącyPróg wyzwalania
Revenue growth decelerates below 6% falsification trigger.MonitorDeterioration versus the report thesis
Operating margins fail to sustain the 20.0% normalized assumption.MonitorDeterioration versus the report thesis
Peer forward P/E multiples compress, dragging the premium valuation.MonitorDeterioration versus the report thesis
Regulatory setbacks in the cardiac rhythm management pipeline.MonitorDeterioration versus the report thesis
Free cash flow conversion drops below 1.0x net income.MonitorDeterioration versus the report thesis

§3 Historia finansowa

Rachunek zysków i strat — ostatnich sześć okresów
PozycjaT−0T−1T−2T−3T−4CAGR
Okres2021-12-312022-12-312023-12-312024-12-312025-12-31Trend
Przychody$11.89B$12.68B$14.24B$16.75B$20.07B+14.0%
Zysk brutto$8.18B$8.73B$9.90B$11.49B$13.85B+14.1%
Zysk operacyjny$1.82B$2.03B$2.42B$3.00B$3.97B+21.5%
Zysk netto$1.04B$698.0M$1.59B$1.85B$2.90B+29.2%
EPS (rozwodniony)$0.69$0.45$1.07$1.25$1.94+29.5%
EBITDA$2.51B$2.75B$3.45B$3.86B$5.10B+19.4%
R&D$1.20B$1.32B$1.41B$1.62B$2.05B+14.3%
SG&A$4.36B$4.52B$5.19B$5.98B$6.89B+12.1%

Wyniki jakości

OCF / Zysk netto
1.57×
>1 wskazuje wysoką jakość wyników
Bramka jakości księgowej
Fail
Bramka skorygowana o sektor
ROIC
8.3%
Zwrot z zainwestowanego kapitału
Sekcja 3

Numbers analysis

Przepływy pieniężne

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

Alokacja kapitału

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Subskrybenci indywidualni — od §411 kolejnych sekcji

Przeczytaj pełną analizę — 11 kolejnych sekcji.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Pełny raport dla każdego pokrytego tickera
24 miesiące archiwum rekomendacji
Briefingi watchlisty + alerty zmian rekomendacji
Eksport PDF + DOCX w dowolnym języku
Rozpocznij darmowy okres próbny
Anuluj w dowolnym momencie.
FAQ

BSX — frequently asked questions

  1. Based on our latest analysis, BSX looks meaningfully undervalued. The current price is $54.1 versus a composite fair-value midpoint of $70.4 (range $55.9–$85.0), which implies roughly 30.1% upside to the midpoint.

Related coverage

Names readers of BSX also follow

Same archetype: mature-compounder